The main highlights for Synairgen in 2015 were the research collaboration with Pharmaxis to develop a compound to treat idiopathic pulmonary fibrosis (IPF) and AstraZeneca commencing a Phase IIa trial of AZD9412 (formally SNG001), the group’s lead inhaled interferon beta programme for virus-induced exacerbations in respiratory diseases. News flow from either isn’t expected until 2017, leading us to believe that 2016 will be a quiet year for the group unless a new opportunity is established. Our ....

21 Jan 2016
Strong prospects but 2016 set to be a quiet year

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong prospects but 2016 set to be a quiet year
Synairgen plc (SNG:LON) | 7.8 0.1 11.6% | Mkt Cap: 15.6m
- Published:
21 Jan 2016 -
Author:
N+1 Singer Team -
Pages:
4 -
The main highlights for Synairgen in 2015 were the research collaboration with Pharmaxis to develop a compound to treat idiopathic pulmonary fibrosis (IPF) and AstraZeneca commencing a Phase IIa trial of AZD9412 (formally SNG001), the group’s lead inhaled interferon beta programme for virus-induced exacerbations in respiratory diseases. News flow from either isn’t expected until 2017, leading us to believe that 2016 will be a quiet year for the group unless a new opportunity is established. Our ....